| Market Capitalization (Millions $) |
6,196 |
| Shares
Outstanding (Millions) |
93 |
| Employees |
497 |
| Revenues (TTM) (Millions $) |
591 |
| Net Income (TTM) (Millions $) |
-43 |
| Cash Flow (TTM) (Millions $) |
3 |
| Capital Exp. (TTM) (Millions $) |
56 |
Business Description
Travere Therapeutics Inc. is a pharmaceutical company that specializes in developing and commercializing treatments for rare and complex diseases. The company was founded in 1988 as Raptor Pharmaceuticals Corp. and was later renamed TRC Capital Corporation in 2018 before changing to its current name in 2019.
Travere Therapeutics focuses on developing treatments for chronic kidney disease, a group of complex and progressive conditions that damage the kidneys over time, leading to a range of health problems. The company has several drugs in its pipeline aimed at treating various forms of chronic kidney disease and other rare disorders.
One of the company's key products is called JYNARQUEe (tolvaptan), a treatment for adult patients with autosomal dominant polycystic kidney disease (ADPKD). ADPKD is a genetic disorder that causes cysts to develop and enlarge in the kidneys, resulting in a range of complications including kidney failure, high blood pressure, and liver cysts. JYNARQUEe is the first FDA-approved treatment for ADPKD and works by decreasing the rate of kidney enlargement and disease progression.
Another product in Travere Therapeutics' pipeline is sparsentan, an investigational drug currently in Phase 3 clinical trials for the treatment of focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN). FSGS and IgAN are two other types of chronic kidney disease that can lead to kidney failure if left untreated.
Travere Therapeutics also has a robust research and development program focused on the development of treatments for other rare and complex diseases. They have partnerships with other pharmaceutical companies and academic institutions to develop new therapies and bring them to market.
In addition to its drug development efforts, Travere Therapeutics is committed to working with patient advocacy groups to raise awareness about rare diseases and improve patient outcomes. The company also has a patient support program that provides assistance to patients who are prescribed its drugs, including financial assistance and access to educational resources.
Overall, Travere Therapeutics is a leading pharmaceutical company specializing in the development of treatments for rare and complex diseases, particularly chronic kidney disease. With an active pipeline of drug candidates and a commitment to patient advocacy, Travere Therapeutics is poised to make a significant impact on the healthcare industry.
Company Address: 3611 Valley Centre Drive San Diego 92130 CA
Company Phone Number: 969-7879 Stock Exchange / Ticker: NASDAQ TVTX
|
168.56 %